AS Diagnosis Research Expanded Rapidly, Then Reoriented After 2021
Diagnostic research in ankylosing spondylitis has grown into a large, uneven literature that mirrors the disease’s own diagnostic difficulty. Across 2008 to 2024, investigators identified 1,205 English-language articles on AS diagnosis from the Web of Science Core Collection, spanning 396 journals and 65 countries. The overall pattern was not one of a single straight line, but of a long expansion phase followed by a visible change in direction after 2021. By the end of the study window, the field had accumulated enough volume to reveal where attention has clustered and where it has thinned.
Diagnostic delay remains the central clinical problem. In the absence of a gold standard, AS often depends on a combination of imaging, symptoms, laboratory findings, and evolving classification language, and that complexity makes early recognition difficult in routine practice. The bibliometric profile reflects exactly that uncertainty: the literature has repeatedly returned to how the disease should be defined, how it should be imaged, and which surrogate markers might improve diagnostic confidence before structural damage becomes obvious.
Where the Literature Concentrated Its Attention
The publication curve reached its highest annual output in 2021, when 111 articles accounted for 9.21% of the total. Citation influence peaked earlier, in 2015, with an average of 5.1 citations per article. Those two peaks do not point to the same moment in the field’s development. Instead, they suggest that the most visible publication growth came later, while some of the most influential papers were already shaping the conversation years before the output surge.
Among journals, Clinical Rheumatology was the most influential outlet, with 76 articles representing 6.31% of the total. China led country productivity with 244 articles, or 20.25% of the corpus. The Berlin Institute of Health ranked first among institutions with 116 articles, 9.63% of the total, and Sieper J was the most productive author, contributing 28 papers, or 2.32%. These patterns point to a field anchored by a relatively small number of high-output centers and authors, even as the overall literature spread across many journals and regions.
The reference network converged on three dominant clusters: “diagnostic criteria,” “therapeutics,” and “recommendations.”
That mix is revealing. Diagnostic work in AS has never been isolated from treatment decisions, because early classification determines access to care, timing of biologic therapy, and the interpretation of axial symptoms that may overlap with other inflammatory disorders. A diagnostic field that repeatedly intersects with therapeutics usually reflects a disease in which classification, prognosis, and treatment eligibility remain tightly linked.
MRI, Mendelian Randomization, and Biomarkers Define the Current Hotspots
The most active current themes are magnetic resonance imaging, Mendelian randomization, and biomarkers. Each of those themes serves a different purpose in the diagnostic pipeline. MRI helps detect inflammatory and structural change before plain radiography becomes definitive. Biomarker research aims to identify blood-based or tissue-based signals that can support earlier recognition. Mendelian randomization serves a different role altogether: it is an etiological adjunct that can help sort causal relationships from correlation and may point toward biomarker discovery, but it does not yet function as a diagnostic test.
That distinction matters in clinic. Genetic inference can guide hypothesis generation, but it does not substitute for a bedside diagnostic tool that can be used in real patients with back pain, equivocal imaging, or incomplete clinical criteria. The bibliometric evidence places Mendelian randomization within the discovery pipeline, not at the point of care. In practical terms, it may help explain why some pathways or biomarkers deserve study, but it does not resolve the problem of delayed diagnosis on its own.
Burst detection identified four emerging post-2021 keywords: “children,” “cells,” “spondyloarthritis,” and “expression.” The rise of “children” points to growing attention to early-onset disease and the challenge of recognizing axial inflammatory disease in younger patients, where symptoms may be nonspecific and structural change may not yet be established. “Cells” and “expression” suggest a stronger push into mechanistic biology, including the molecular and cellular signals that might eventually translate into diagnostic markers. The appearance of “spondyloarthritis” also reflects a terminological shift that has influenced how the literature is indexed and interpreted.
A Slower Recent Pace Does Not Mean Scientific Stagnation
The period from 2008 to 2021 functioned as the growth phase of AS diagnostic research, while 2022 to 2024 appeared more transitional and reoriented. The apparent slowdown in recent years does not point to a simple loss of momentum. Instead, the bibliometric pattern is shaped by changing terminology between AS and radiographic axial spondyloarthritis, by time-lag bias in citation tracking, and by the persistent difficulty of extracting specific pathophysiological signals from a disease that often declares itself gradually.
The field is still constrained by the same core problem: AS lacks a single defining clinical feature that can reliably anchor diagnosis across all patients. That absence keeps imaging, biomarkers, genetics, and classification systems in continuous motion, each trying to compensate for the others’ limitations. A bibliometric review cannot solve those diagnostic gaps, but it can show where the field is investing its effort and which concepts are gaining traction.
For now, the literature suggests that the strongest momentum lies in imaging-led detection, mechanistic biomarker discovery, and causal inference tools that may refine future research questions. None of those elements has become a standalone diagnostic standard. The next phase of progress will depend on whether these separate lines of inquiry can be tied to earlier, more specific, and more clinically usable recognition of ankylosing spondylitis.